GO:0090194 negative regulation of glomerulus development: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090194 describes any biological process that decreases the rate, frequency or extent of glomerulus development, the progression of the glomerulus from initial formation to its mature state.
• Negative regulation of glomerulus development is essential for preventing excessive or aberrant capillary tuft formation and for maintaining normal nephron architecture.
• Key molecular players include angiogenic factors such as VEGF-A and BMP9, which influence glomerular endothelial cell identity and microvasculature formation.
• Dysregulation of this process contributes to glomerular diseases including membranous nephropathy, C3 glomerulopathy, and diabetic podocytopathy.
• Inflammatory signaling and complement activation can accelerate glomerular injury, highlighting the importance of negative regulatory checkpoints.
• CRISPR-based knockout, knock-in, and overexpression models are powerful tools for dissecting the causal roles of genes that negatively regulate glomerulus development.
Description
The glomerulus is a specialized capillary tuft surrounded by Bowman's capsule that performs the first step of blood filtration in the vertebrate kidney. Its development is a tightly orchestrated process requiring precise temporal and spatial control of cell proliferation, differentiation, migration, and angiogenesis. The Gene Ontology term GO:0090194, negative regulation of glomerulus development, captures any process that decreases the rate, frequency or extent of this developmental progression. Understanding the negative regulators of glomerulus development is critical because insufficient or excessive suppression can lead to malformed glomeruli, impaired filtration, and progressive kidney disease. Research into this term spans developmental biology, nephrology, and vascular biology, with direct relevance to human conditions such as membranous nephropathy, C3 glomerulopathy, and diabetic nephropathy. This article synthesizes current knowledge on the mechanisms, key genes, and experimental models used to study negative regulation of glomerulus development, providing a resource for researchers designing CRISPR-based functional studies.
negative regulation of glomerulus development At A Glance
| GO ID | GO:0090194 |
|---|---|
| GO term | negative regulation of glomerulus development |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency or extent of glomerulus development, ensuring proper nephron formation and preventing aberrant capillary tuft expansion |
| Related process | Positive regulation of glomerulus development, glomerulus morphogenesis, glomerular filtration barrier assembly |
| Key regulators | VEGF-A, BMP9, ROCK2, DKK3, FOXF1, EZH2, and inflammatory signaling pathways |
| Disease relevance | Membranous nephropathy, C3 glomerulopathy, diabetic podocytopathy, renal fibrosis |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, imaging of glomerular development in model organisms |
What Is GO:0090194?
GO:0090194 negative regulation of glomerulus development is defined as any process that decreases the rate, frequency or extent of glomerulus development, the progression of the glomerulus over time from its initial formation until its mature state. The glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney. This term encompasses molecular signals, cellular interactions, and extracellular cues that restrain or terminate developmental programs to ensure proper glomerular architecture and function.
Why Is negative regulation of glomerulus development Important in Cell Biology?
Negative regulation of glomerulus development is fundamental for kidney health because it prevents excessive or disorganized capillary tuft formation that would compromise filtration. Disruption of these regulatory checkpoints is linked to a spectrum of glomerular diseases, including immune-mediated membranous nephropathy, complement-driven C3 glomerulopathy, and metabolic podocytopathies such as diabetic nephropathy. Moreover, inflammatory signals and complement activation can override negative regulatory mechanisms, accelerating glomerular injury. Studying this GO term therefore provides insights into disease pathogenesis and identifies potential therapeutic targets for preserving kidney function.
• Maintains proper glomerular architecture by restraining developmental programs after maturation.
• Prevents aberrant angiogenesis and capillary tuft expansion in the glomerulus.
• Protects against immune-mediated glomerular injury by limiting inflammatory amplification.
• Dysregulation contributes to membranous nephropathy, a leading cause of nephrotic syndrome in adults.
• Loss of negative regulation is implicated in C3 glomerulopathy, where complement dysregulation drives glomerular damage.
• Metabolic stress in diabetic podocytopathy involves ROCK2-mediated rewiring that may bypass negative regulatory signals.
• Senescence of tubular epithelial cells regulated by DKK3 can trigger glomerular endothelial ferroptosis and fibrosis.
• BMP9 signaling is critical for endothelial identity, and its loss induces arteriovenous malformations, highlighting its role in vascular negative regulation.
• Understanding these mechanisms aids in developing targeted therapies for chronic kidney disease.
• Provides a framework for CRISPR-based functional genomics of kidney development and disease.
What Happens During negative regulation of glomerulus development?
Initiation of negative regulatory signals
In simple terms: The body sends stop signals to prevent the glomerulus from growing too much.
Negative regulation of glomerulus development begins when molecular cues instruct cells to halt or slow developmental programs. These cues can originate from neighboring cells, the extracellular matrix, or systemic factors. For example, BMP9 is a key player in endothelial identity, and its loss is sufficient to induce arteriovenous malformations, indicating that BMP9 signaling normally acts to maintain proper vascular identity and restrict aberrant glomerular angiogenesis. Similarly, polysialic acid interacts with VEGF-A188 to regulate glomerular microvasculature formation, and disruption of this interaction can lead to excessive or disorganized vessel growth. These initial signals set the stage for downstream events that suppress glomerular development.
Suppression of angiogenic sprouting
In simple terms: Signals tell new blood vessels in the glomerulus to stop sprouting.
Once negative regulatory signals are received, they converge on pathways that suppress angiogenic sprouting. VEGF-A is a potent pro-angiogenic factor, but its isoforms and interactions with polysialic acid can modulate its activity to limit excessive vessel formation. The balance between pro- and anti-angiogenic signals determines whether glomerular capillaries expand or remain quiescent. Disruption of this balance, as seen when BMP9 is lost, leads to arteriovenous malformations and abnormal vascular patterning. Thus, negative regulation at this stage ensures that the glomerular capillary tuft reaches an appropriate size and architecture.
Restraint of podocyte proliferation and differentiation
In simple terms: Podocytes, the specialized cells of the glomerulus, are kept from multiplying too much.
Podocytes are essential for the glomerular filtration barrier, and their proliferation and differentiation must be tightly controlled. Negative regulatory mechanisms restrain podocyte cell cycle progression and promote their terminal differentiation. In diabetic podocytopathy, ROCK2-induced metabolic rewiring contributes to podocyte injury, suggesting that ROCK2 activity can override negative regulatory checkpoints. Additionally, DKK3, regulated by the FOXF1-EZH2 axis, acts on tubular epithelial cells to trigger senescence and subsequent glomerular endothelial cell ferroptosis, linking tubular-podocyte crosstalk to negative regulation of glomerular development and fibrosis. These findings highlight how negative regulation integrates signals from multiple cell types to maintain glomerular homeostasis.
Modulation of inflammatory and complement pathways
In simple terms: The immune system's attack on the glomerulus is kept in check.
Inflammatory and complement pathways can accelerate glomerular injury, and negative regulatory mechanisms exist to dampen these responses. For instance, immunoglobulin A receptor (FcαRI) negatively regulates inflammatory responses and inhibits the development of Toll-like receptor-9 signaling-accelerated glomerulonephritis. In C3 glomerulopathy, dysregulation of the alternative complement pathway leads to glomerular damage, indicating that negative regulation of complement activation is crucial for glomerular health. These immune-modulatory checkpoints represent an important facet of negative regulation of glomerulus development, particularly in the context of immune-mediated diseases.
Termination and stabilization of the mature glomerulus
In simple terms: Once the glomerulus is fully formed, stop signals keep it stable.
After the glomerulus reaches its mature state, negative regulatory processes maintain its stability and prevent reactivation of developmental programs. This includes sustained suppression of angiogenic and proliferative signals. In membranous nephropathy, autoantibodies against phospholipase A2 receptor (PLA2R) and other antigens drive podocyte injury, and the loss of negative regulatory control contributes to disease progression. Similarly, in renal fibrosis, tubular epithelial cell senescence regulated by DKK3 can trigger glomerular endothelial cell ferroptosis, indicating that failure of negative regulation can lead to pathological remodeling. Thus, termination and stabilization are active processes essential for long-term kidney function.
Key Genes Involved in GO:0090194 negative regulation of glomerulus development
The following genes and proteins have been implicated in negative regulation of glomerulus development or related glomerular disease processes, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGF-A | Regulates angiogenesis and vascular permeability; interaction with polysialic acid modulates glomerular microvasculature formation | Target for studying angiogenic balance in glomerular development and disease |
| BMP9 | Endothelial identity and prevention of arteriovenous malformations; loss induces abnormal vascular patterning | Key regulator of vascular negative regulation; potential therapeutic target |
| ROCK2 | Metabolic rewiring in diabetic podocytopathy; contributes to podocyte injury | Implicated in metabolic kidney disease; candidate for CRISPR knockout studies |
| DKK3 | Regulated by FOXF1-EZH2; acts on tubular epithelial cells to trigger senescence and glomerular endothelial ferroptosis | Links tubular injury to glomerular dysfunction; target for fibrosis research |
| FOXF1 | Transcription factor regulating DKK3 expression | Upstream regulator of negative regulatory pathways in kidney |
| EZH2 | Epigenetic regulator in the FOXF1-EZH2 axis controlling DKK3 | Epigenetic modifier; potential target for modulating gene expression |
| PLA2R | Autoantigen in primary membranous nephropathy; podocyte injury | Diagnostic and therapeutic target in nephrotic syndrome |
| FcαRI | Negatively regulates inflammatory responses; inhibits TLR9-accelerated glomerulonephritis | Immune receptor modulating glomerular inflammation |
| TLR9 | Inflammatory signaling pathway accelerated glomerulonephritis | Innate immune sensor; target for anti-inflammatory strategies |
| C3 | Central component of complement cascade; dysregulation in C3 glomerulopathy | Complement factor; biomarker and therapeutic target |
| Complement factor H | Regulates alternative complement pathway; mutations associated with C3 glomerulopathy | Key negative regulator of complement; genetic studies relevant |
| Podocin | Structural protein of podocyte slit diaphragm; mutations cause nephrotic syndrome | Model for podocyte differentiation and glomerular development |
| Nephrin | Essential for glomerular filtration barrier; mutations cause congenital nephrotic syndrome | Target for studying podocyte biology and negative regulation |
| WT1 | Transcription factor required for kidney development; mutations cause Wilms tumor and nephropathy | Master regulator of nephron formation |
| Pax2 | Transcription factor in kidney development; mutations cause renal anomalies | Early developmental regulator; knockout models available |
| Pax8 | Transcription factor in kidney and thyroid development | Co-regulator with Pax2 in nephrogenesis |
| Lmx1b | Transcription factor in podocyte differentiation; mutations cause nail-patella syndrome with nephropathy | Links developmental regulation to glomerular disease |
| Wnt4 | Signaling molecule in kidney development; regulates mesenchymal-to-epithelial transition | Pathway for negative regulation of glomerular differentiation |
How Is negative regulation of glomerulus development Regulated?
Negative regulation of glomerulus development is controlled by a network of signaling pathways and transcription factors. The FOXF1-EZH2 axis regulates DKK3 expression, which in turn affects tubular epithelial cell senescence and glomerular endothelial cell ferroptosis, linking epigenetic control to negative regulation. ROCK2-mediated metabolic rewiring in diabetic podocytopathy suggests that metabolic pathways can modulate negative regulatory checkpoints. Additionally, inflammatory signaling through TLR9 and FcαRI influences the progression of glomerulonephritis, indicating that immune pathways intersect with developmental negative regulation. Complement regulators such as factor H are critical for preventing C3 glomerulopathy, highlighting the role of complement inhibition as a negative regulatory mechanism. These diverse regulatory inputs ensure that glomerulus development is appropriately restrained in response to physiological and pathological cues.
negative regulation of glomerulus development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLA2R | Primary membranous nephropathy | Knockout or knock-in of PLA2R in podocytes to study autoantibody binding |
| Complement factor H | C3 glomerulopathy | Point mutation knock-in in mice to model complement dysregulation |
| ROCK2 | Diabetic podocytopathy | Podocyte-specific knockout or overexpression in diabetic mouse models |
| DKK3 | Renal fibrosis | Tubular epithelial cell-specific knockout or FOXF1-EZH2 axis manipulation |
| FcαRI | TLR9-accelerated glomerulonephritis | Knockout mice to assess inflammatory regulation in glomeruli |
Membranous Nephropathy
Primary membranous nephropathy is an autoimmune disease characterized by autoantibodies against podocyte antigens such as PLA2R, leading to complement activation and podocyte injury. The loss of negative regulatory mechanisms that normally restrain immune responses and complement activation contributes to disease progression. Understanding how negative regulation of glomerulus development is subverted in membranous nephropathy may reveal new therapeutic targets.
C3 Glomerulopathy
C3 glomerulopathy is a rare kidney disease caused by dysregulation of the alternative complement pathway, often due to mutations in complement factor H or autoantibodies against C3 convertase. The absence of proper negative regulation of complement activation leads to glomerular damage. This condition exemplifies how failure of negative regulatory processes can result in glomerular disease.
Diabetic Podocytopathy
Diabetic nephropathy involves podocyte injury and loss, contributing to proteinuria and progressive kidney failure. ROCK2-induced metabolic rewiring in podocytes is implicated in diabetic podocytopathy, suggesting that metabolic stress can override negative regulatory signals that normally protect podocytes. Targeting ROCK2 or related pathways may restore negative regulation and slow disease progression.
Renal Fibrosis
Renal fibrosis is a common end-stage consequence of chronic kidney disease. DKK3, regulated by FOXF1-EZH2, promotes tubular epithelial cell senescence and triggers glomerular endothelial cell ferroptosis, linking negative regulatory failure to fibrosis. This highlights the importance of negative regulation in preventing pathological remodeling of the glomerulus.
From negative regulation of glomerulus development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate glomerulus development? | CRISPR knockout in zebrafish or mouse kidney organoids |
| What is the effect of a specific point mutation in a negative regulator? | CRISPR point mutation knock-in in podocyte cell lines or mice |
| How does overexpression of a candidate gene affect glomerular architecture? | CRISPR-mediated overexpression (e.g., CRISPRa) in kidney organoids |
| Where and when is the protein of interest expressed during glomerulogenesis? | Tagged knock-in (e.g., GFP) in mouse or human iPSC-derived kidney organoids |
| What are the downstream targets of a negative regulator? | RNA-seq and proteomics after CRISPR knockout or overexpression |
| Can a candidate gene rescue a disease phenotype? | Knock-in of wild-type or mutant allele in disease model |
How to Study the negative regulation of glomerulus development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify pathways altered by CRISPR knockout of negative regulators |
| Proteomics | Protein abundance and modifications | Study signaling rewiring in podocytopathy models |
| Phosphoproteomics | Phosphorylation events | Map kinase cascades downstream of ROCK2 or BMP9 |
| Confocal microscopy | Morphology and protein localization | Visualize glomerular capillary tuft and podocyte architecture |
| Light-sheet microscopy | 3D developmental dynamics | Track glomerulus formation in zebrafish or organoids |
| CRISPR screening | Phenotypic effects of gene knockout | Identify novel negative regulators of glomerulus development |
| Kidney organoid assays | Filtration barrier function | Model membranous nephropathy and C3 glomerulopathy |
Transcriptomic Profiling
RNA sequencing (RNA-seq) is widely used to identify gene expression changes during glomerulus development and in disease models. By comparing wild-type and CRISPR knockout models, researchers can uncover pathways that are negatively regulated. For example, RNA-seq of podocytes with ROCK2 manipulation revealed metabolic rewiring in diabetic podocytopathy. Similarly, transcriptomic analysis of kidney organoids can reveal the impact of BMP9 loss on endothelial identity.
Proteomic and Phosphoproteomic Analysis
Mass spectrometry-based proteomics allows quantification of protein abundance and post-translational modifications. This is particularly useful for studying signaling pathways such as ROCK2, where phosphorylation events drive metabolic rewiring. Proteomics can also identify protein-protein interactions involving negative regulators like DKK3 and its downstream effectors.
Imaging of Glomerular Development
Advanced imaging techniques, including confocal and light-sheet microscopy, enable visualization of glomerular development in model organisms such as zebrafish and mice. These methods can assess capillary tuft formation, podocyte migration, and vascular patterning. For instance, studies on polysialic acid and VEGF-A188 interactions used imaging to demonstrate effects on glomerular microvasculature. Similarly, BMP9 loss was visualized as arteriovenous malformations in endothelial cells.
Functional Assays in Kidney Organoids
Human induced pluripotent stem cell (iPSC)-derived kidney organoids provide a tractable system for modeling glomerulus development and disease. CRISPR-based gene editing in organoids allows functional interrogation of candidate negative regulators. Organoids can be subjected to filtration assays, permeability tests, and immunofluorescence for glomerular markers. This approach has been used to study podocyte biology and complement-mediated injury.
How CRISPR Can Be Used to Study GO:0090194 negative regulation of glomerulus development
Knockout
CRISPR knockout is used to completely ablate a candidate gene to determine whether it is necessary for negative regulation of glomerulus development. For example, knocking out BMP9 in endothelial cells induced arteriovenous malformations, demonstrating its essential role in vascular identity. Similarly, knockout of FcαRI exacerbated TLR9-accelerated glomerulonephritis, confirming its negative regulatory function in inflammation. Knockout models can be generated in cell lines, kidney organoids, or animal models to assess effects on glomerular architecture and function.
Point Mutation
CRISPR point mutation knock-in allows introduction of specific disease-associated mutations to study their impact on protein function. This is particularly relevant for complement factor H mutations in C3 glomerulopathy, where single amino acid changes can impair negative regulation of complement. Point mutations can also be used to dissect phosphorylation sites or interaction domains in signaling proteins like ROCK2.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) or epitope tags enables visualization and quantification of endogenous protein expression. Tagged knock-in of podocyte markers such as nephrin or podocin can reveal their spatiotemporal expression during glomerulus development. Additionally, knock-in of human disease alleles into mouse models can recapitulate human glomerular diseases for preclinical testing.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression constructs can be used to increase expression of candidate negative regulators. Overexpression of DKK3 in tubular epithelial cells triggered senescence and glomerular endothelial ferroptosis, linking its gain-of-function to fibrosis. Overexpression studies help determine whether a gene is sufficient to suppress glomerulus development or protect against injury.
How EDITGENE Supports negative regulation of glomerulus development Research
Researchers studying negative regulation of glomerulus development-related genes often need to determine whether a candidate gene is causally involved in restraining developmental programs or protecting against glomerular disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point mutation models to knock-in reporters and overexpression systems, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of glomerulus development research.
Frequently Asked Questions About negative regulation of glomerulus development
What is GO:0090194 negative regulation of glomerulus development?
GO:0090194 is a Gene Ontology biological process term defined as any process that decreases the rate, frequency or extent of glomerulus development, the progression of the glomerulus from initial formation to its mature state.
What genes are involved in negative regulation of glomerulus development?
Key genes include VEGF-A, BMP9, ROCK2, DKK3, FOXF1, EZH2, FcαRI, complement factor H, and PLA2R, among others.
How does BMP9 regulate glomerulus development?
BMP9 is a key player in endothelial identity, and its loss is sufficient to induce arteriovenous malformations, indicating that BMP9 signaling normally acts to maintain proper vascular identity and restrict aberrant glomerular angiogenesis.
What is the role of ROCK2 in diabetic podocytopathy?
ROCK2-induced metabolic rewiring in podocytes contributes to diabetic podocytopathy, suggesting that ROCK2 activity can override negative regulatory checkpoints and lead to podocyte injury.
How is DKK3 involved in renal fibrosis?
DKK3, regulated by the FOXF1-EZH2 axis, acts on tubular epithelial cells to trigger senescence and subsequent glomerular endothelial cell ferroptosis, linking tubular injury to glomerular dysfunction and fibrosis.
What diseases are associated with dysregulation of negative regulation of glomerulus development?
Diseases include primary membranous nephropathy, C3 glomerulopathy, diabetic podocytopathy, and renal fibrosis.
What experimental models are used to study negative regulation of glomerulus development?
Models include CRISPR knockout mice, kidney organoids, zebrafish, and podocyte cell lines, combined with RNA-seq, proteomics, and imaging.
How can CRISPR be used to study negative regulation of glomerulus development?
CRISPR knockout, point mutation knock-in, tagged knock-in, and overexpression (CRISPRa) enable functional interrogation of candidate genes in cell lines and organoids.
What is the role of complement factor H in C3 glomerulopathy?
Complement factor H is a key negative regulator of the alternative complement pathway; mutations in factor H are associated with C3 glomerulopathy, leading to glomerular damage.
Why is negative regulation of glomerulus development important for kidney health?
It prevents excessive or disorganized capillary tuft formation, maintains filtration barrier integrity, and protects against immune-mediated and metabolic glomerular injury.
Conclusion
Negative regulation of glomerulus development (GO:0090194) is a critical biological process that restrains developmental programs to ensure proper glomerular architecture and function. Dysregulation of this process contributes to a range of kidney diseases, including membranous nephropathy, C3 glomerulopathy, diabetic podocytopathy, and renal fibrosis. Advances in CRISPR-based gene editing, combined with transcriptomics, proteomics, and imaging, are enabling researchers to dissect the molecular players and pathways involved. EDITGENE offers comprehensive services to support these studies, from knockout and knock-in models to library screening and bioinformatics, empowering the discovery of new therapeutic targets for glomerular diseases.
References
- 1. Gu Y et al.. 2021. Mechanisms of Primary Membranous Nephropathy.. Biomolecules 11(4) PMID: 33808418
- 2. Watanabe T et al.. 2011. Negative regulation of inflammatory responses by immunoglobulin A receptor (FcαRI) inhibits the development of Toll-like receptor-9 signalling-accelerated glomerulonephritis.. Clin Exp Immunol 166(2):235-50 PMID: 21985370
- 3. Barbour TD et al.. 2016. Update on C3 glomerulopathy.. Nephrol Dial Transplant 31(5):717-25 PMID: 25326473
- 4. Desroches-Castan A et al.. 2024. BMP9 is a key player in endothelial identity and its loss is sufficient to induce arteriovenous malformations.. Cardiovasc Res 120(7):782-795 PMID: 38502919
- 5. Dressler GR. 2006. The cellular basis of kidney development.. Annu Rev Cell Dev Biol 22:509-29 PMID: 16822174
- 6. Cao H et al.. 2025. DKK3, regulated by FOXF1-EZH2 axis, takes action on tubular epithelial cells senescence to trigger glomerular endothelial cells ferroptosis involving in renal fibrosis.. Mech Ageing Dev 228:112103 PMID: 40885212
- 7. Matoba K et al.. 2022. ROCK2-induced metabolic rewiring in diabetic podocytopathy.. Commun Biol 5(1):341 PMID: 35396346
- 8. Niculovic KM et al.. 2025. Polysialic acid regulates glomerular microvasculature formation by interaction with VEGF-A188 in mice.. Angiogenesis 28(3):31 PMID: 40411622
